Wegovy pill weight loss results in trials show about 13-15% body weight loss over a year. See how oral semaglutide compares with the injection.
The Wegovy pill (oral semaglutide) has produced average weight loss of roughly 13% to 15% of total body weight in late-stage clinical trials, which works out to about 30 to 35 pounds for a person starting around 230 pounds. Those results come from studies of once-daily oral semaglutide at 25 mg and 50 mg, and they look broadly similar to results from the weekly Wegovy injection. Individual results vary a lot based on dose, how long treatment continues, and daily nutrition and activity habits.
How Much Weight Do People Lose on the Wegovy Pill?
Novo Nordisk ran a series of OASIS trials testing oral semaglutide at different doses for chronic weight management. The averages below come from participants who completed the studies, which matters: people who stopped early because of side effects are not included in the headline numbers.
| Trial | Daily Dose | Treatment Length | Average Weight Loss | Placebo |
|---|---|---|---|---|
| OASIS 1 | 50 mg | 68 weeks | About 15.1% | About 2.4% |
| OASIS 4 | 25 mg | 64 weeks | About 13.6% | About 2.2% |
A meaningful share of participants — roughly a third in the 25 mg trial — lost 15% or more of their body weight. Weight loss was still trending downward for many people when the trials ended, which suggests a longer course could produce more. If you are researching semaglutide pill weight loss, these trial averages are the most reliable benchmark available right now.
For comparison, the injectable Wegovy pen at 2.4 mg weekly produced about 14.9% average weight loss at 68 weeks in the STEP 1 trial. No head-to-head trial has directly compared the pill and the injection, so the comparison rests on separate studies of the same drug.
Oral Wegovy vs. Injectable Wegovy
The two forms share an active ingredient but differ in logistics, dosing, and how people tend to use them day to day.
| Feature | Wegovy Pill (Oral Semaglutide) | Wegovy Injection |
|---|---|---|
| How it is taken | Once daily by mouth | Once weekly under the skin |
| Maintenance dose studied | 25 mg | 2.4 mg |
| Average trial weight loss | About 13.6% at 64 weeks | About 14.9% at 68 weeks |
| Common friction point | Timing around food, water, and other medications | Needle handling and refrigeration |
People who dislike needles often prefer the pill, while others find a weekly injection easier to remember than a daily tablet. Oral semaglutide absorption is sensitive to how and when it is taken, so following label instructions closely matters.
The injectable form of Wegovy is FDA-approved for chronic weight management in the United States. Oral semaglutide for obesity has been submitted for FDA review, and approval status can change quickly, so confirm the current label with your prescriber or pharmacist.
What the First Weeks and Months Look Like
Most people do not see dramatic scale changes in week one. Appetite changes usually arrive first, often within one to two weeks, followed by gradual weight loss as daily calorie intake falls.
- Weeks 1-4: appetite suppression and possible nausea; modest weight change, often only 1-3 pounds.
- Weeks 4-12: steadier loss as the dose escalates; many people see 5-8% of body weight gone by the three-month mark.
- Months 3-12: the largest losses accumulate, and the 13-15% trial averages reflect a full year at maintenance dose.
Many people search for ozempic weight loss results 1 month to set an early benchmark, and the honest answer is the same for any semaglutide product: one month is too soon to judge success. The dose is still being titrated, and the biggest changes come later.
Side Effects and Safety Considerations
Gastrointestinal effects dominate the side effect profile for both the pill and the injection. Nausea, vomiting, diarrhea, and constipation are the most commonly reported issues, and they often ease as the body adjusts.
Rare but serious risks include pancreatitis, gallbladder disease, and bowel obstruction. Semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodents and is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Semaglutide is a prescription medication, and anyone considering it should review their full medical history, current medications, and pregnancy plans with a licensed healthcare professional.
Muscle loss is another consideration during rapid weight reduction. Higher protein intake and resistance training help protect lean mass while the scale drops.
How the Wegovy Pill Compares With Other Weight Loss Options
Oral semaglutide sits in a crowded and fast-moving field. Tirzepatide (Zepbound) has shown higher average weight loss in its own trials, and several new compounds are in late-stage development.
Pipeline questions come up constantly, including when will eli lilly weight loss pill be available, since an oral GLP-1 candidate is moving through FDA review. Availability dates depend on regulatory decisions and can shift, so treat any announced timeline as provisional.
People also ask whether non-GLP-1 compounds help, such as does bpc-157 help with weight loss. BPC-157 is not FDA-approved for human use in the United States, and there is no solid clinical evidence that it drives meaningful weight loss in people.
Supplement curiosity runs high too, and searches like l carnitine weight loss results 1 month reflect that interest. L-carnitine may support small changes in body composition in some studies, but the effect size is far smaller than what GLP-1 medications produce.
Questions to Ask Your Doctor Before Starting
- Does my BMI or health history fall within the label criteria for semaglutide?
- Which form, pill or injection, fits my routine and preferences better?
- How will we manage side effects if they interfere with work or daily life?
- What dose escalation schedule will I follow, and when do we reassess progress?
- How should I time the pill around food, water, and my other medications?
It also helps to ask what happens if you stop. Weight regain after stopping semaglutide is common, and the STEP 1 extension showed participants regained roughly two-thirds of their lost weight within a year of discontinuing treatment.
Weight loss results on the Wegovy pill are real, but they are averages from people who stayed on treatment for a year or more. Steady habits, follow-up visits, and realistic expectations matter as much as the prescription itself.
Frequently Asked Questions
How much weight can you lose on the Wegovy pill?
In the OASIS trials, once-daily oral semaglutide produced average weight loss of about 13.6% at the 25 mg dose over 64 weeks and about 15.1% at the 50 mg dose over 68 weeks. For someone starting around 230 pounds, that is roughly 30 to 35 pounds. Individual results vary based on dose, treatment duration, and lifestyle factors.
Is the Wegovy pill as effective as the Wegovy injection?
The two forms have not been compared head-to-head in a single trial, but their separate trial averages are close: about 13.6% for the 25 mg pill and about 14.9% for the 2.4 mg weekly injection. Response varies from person to person regardless of which form is used. Your prescriber can help you choose based on preferences and medical history.
How long does it take to see weight loss results with the Wegovy pill?
Appetite changes often show up within one to two weeks, while measurable weight loss usually becomes clear around four to eight weeks as the dose increases. The largest losses typically accumulate between three and twelve months of consistent treatment. One month is generally too early to judge whether the medication is working.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.